Bellerophon Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2014 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Bellerophon Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2014 to Q3 2023.
  • Bellerophon Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$2.17M, a 57.6% increase year-over-year.
  • Bellerophon Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$11M, a 48.8% increase year-over-year.
  • Bellerophon Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$22.4M, a 11% decline from 2021.
  • Bellerophon Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$20.2M, a 23.3% increase from 2020.
  • Bellerophon Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$26.3M, a 50.4% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$11M -$2.17M +$2.95M +57.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$14M -$5.26M +$1.28M +19.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$15.3M $1.48M +$7.12M Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$22.4M -$5.09M -$812K -19% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 -$21.6M -$5.12M -$313K -6.52% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$21.3M -$6.54M -$1.32M -25.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$19.9M -$5.64M +$217K +3.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$20.2M -$4.27M +$3.87M +47.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$24M -$4.8M +$3.46M +41.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$27.5M -$5.23M +$533K +9.26% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$28M -$5.86M -$1.75M -42.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$26.3M -$8.15M -$3.83M -88.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-11
Q3 2020 -$22.4M -$8.26M -$3.67M -79.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$18.8M -$5.76M -$1.53M -36.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$17.2M -$4.11M +$232K +5.34% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$17.5M -$4.32M +$369K +7.88% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$17.8M -$4.59M +$2.24M +32.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-11
Q2 2019 -$20.1M -$4.23M +$3.65M +46.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-11
Q1 2019 -$23.7M -$4.34M +$4.15M +48.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-11
Q4 2018 -$27.9M -$4.68M +$2.63M +35.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-04-06
Q3 2018 -$30.5M -$6.83M -$647K -10.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-04-06
Q2 2018 -$29.9M -$7.87M -$1.55M -24.5% Apr 1, 2018 Jun 30, 2018 10-K 2020-04-06
Q1 2018 -$28.3M -$8.49M -$3.71M -77.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-04-06
Q4 2017 -$24.6M -$7.31M -$17K -0.23% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$24.6M -$6.18M -$1.97M -46.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$22.6M -$6.32M -$1.16M -22.6% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$21.5M -$4.78M +$2.31M +32.5% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$23.8M -$7.29M +$3.57M +32.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$27.3M -$4.22M +$6.95M +62.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$34.3M -$5.16M +$6.45M +55.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$40.7M -$7.09M +$5.84M +45.2% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$46.6M -$10.9M +$1.93M +15.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-13
Q3 2015 -$48.5M -$11.2M +$4.32M +27.9% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-13
Q2 2015 -$52.8M -$11.6M +$5.35M +31.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-13
Q1 2015 -$58.2M -$12.9M +$1.58M +10.9% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-13
Q4 2014 -$59.8M -$12.8M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-21
Q3 2014 -$15.5M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-21
Q2 2014 -$17M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-21
Q1 2014 -$14.5M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.